These findings indicate that chronic treatment with DPP‐4 inhibitors can have a significant impact on body weight control and energy homeostasis by modulating BAT activity, providing validation of DPP‐4 inhibition as a viable therapeutic option for the treatment of metabolic disorders related to diabetes and obesity. Here, DPP4 is linked to diabetes mellitus.